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Introduction
In patients undergoing maintenance haemodialysis,
hepatitis C virus (HCV) infection is common and may
lead to severe complications such as chronic hepatitis,
cirrhosis and hepatocellular carcinoma. It is recom-
mended to eradicate HCV infection in dialysis
patients awaiting renal transplantation and those with
acute hepatitis C or signiﬁcant chronic liver disease.
Interferon-a-2a in monotherapy thrice weekly, which
is the standard treatment for HCV infection in this
setting, has many drawbacks such as poor tolerance
and marginal response [1]. The addition of ribavirin
is generally contra-indicated in these patients due to a
risk of haemolytic anaemia. Pegylated interferon was
developed by attaching a large polyethylene glycol
(PEG) moiety (40 kDa) to interferon in order to
confer greater stability and prolonged systemic expo-
sure to allow once-weekly administration [2]. In two
randomized controlled trials, PEG–interferon-a-2a
in monotherapy was more efﬁcient than conventional
interferon for the treatment of HCV infection asso-
ciated with chronic liver disease [3,4]. Currently, there
is no published experience concerning the use of this
compound in patients with end-stage renal disease
(ESRD).
Cases
Between January 2002 and April 2003, two HCV
patients with biopsy-proven chronic liver disease
and one patient with acute hepatitis C were treated
with PEG–interferon-a-2a in our institution. Clinical
characteristics were as follows.
Case 1
Patient 1 was a 37-year-old male patient known for
ESRD due to chronic interstitial nephritis and dialysed
since 1992. HCV infection was diagnosed in 1996,
following routine screening. A renal transplantation
was performed in 1997 but dialysis was resumed in 2000
because of chronic allograft rejection. He was then
considered for a second renal transplantation. A pre-
transplant evaluation revealed persistent elevation of
liver enzymes and positivity for antibodies to HCV.
The HCV genotype was 1b. The HCV RNA level was
290 kIU/ml. A liver biopsy showed moderately active
hepatitis and ﬁbrosis (Metavir score A2F2).
Case 2
Patient 2 was a 61-year-old man on dialysis for ESRD
secondary to vascular and hypertensive nephropathy.
He received a cadaveric renal allograft in 1987 and was
found to be positive for anti-HCV antibodies in 1991,
presumably consecutive to graft transmission. Chronic
hepatitis C progressively developed, and liver cirrhosis
Child A was diagnosed in 2000. Dialysis consequently
was resumed and the transplant removed in 2002. A
double kidney–liver transplantation was considered. A
liver biopsy conﬁrmed moderate micronodular cirrho-
sis (Metavir score F4). Liver enzymes were normal and
HCV RNA level was 253 kIU/ml. Typing revealed
HCV genotype 3a.
Case 3
Patient 3 was a 56-year-old man who had been
undergoing haemodialysis since 2001 because of
ESRD due to autosomal dominant polycystic kidney
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disease. In January 2002, he suddenly developed
nausea, vomiting, diarrhoea, fatigue and frank eleva-
tion of liver enzymes. Acute hepatitis C was diagnosed.
Although the cause of HCV infection was not clearly
identiﬁed, exposure to infected material from the
haemodialysis setting was thought to be the most
likely source. The HCV RNA level in serum was
594 kIU/ml and HCV genotype was 1b.
Treatment
Each patient was scheduled to receive subcutaneous
treatment with PEG–interferon-a-2a (Pegasys,
Roche, Basle, Switzerland) over 48 weeks, starting at
180 mg once weekly, immediately following the dialysis
session. Patients were monitored by weekly blood
formulae and a precise dose-adjustment schedule
according to blood cell count; patient clinical tolerance
was applied according to the manufacturer’s recom-
mendations (Table 1). During the treatment period, the
patients underwent three dialysis sessions of 3 h 30min
per week through high-ﬂux polysulfone dialysers.
The HCV RNA level was determined in serum
by polymerase chain reaction (PCR) assay (Cobas
Amplicor HCV Monitor assay, Roche Diagnostics
Systems) immediately before the haemodialysis session.
Samples were collected at the following time points:
1–4 weeks before the treatment was started, during the
treatment at weeks 12, 24 and 48, and 6 months after
the end of the treatment, i.e. at week 72. The absence
of detectable levels of HCV RNA was deﬁned as
<50 IU/ml. Sustained virological response (SVR) was
deﬁned as the absence of detectable levels of HCV
RNA in serum at 72 weeks, i.e. 6 months after the end
of treatment. Genotype analysis was carried out by
reverse transcriptase–PCR followed by hybridization
of ampliﬁed products on an array of genotype-speciﬁc
probes [Versant HCV genotype assay (LiPA), Bayer].
The applied treatment and clinical follow-up of the
patients are summarized in Table 2. HCV RNA was
undetectable in all three patients after 12 weeks of
therapy. In patients 1 and 3 (genotype 1b), HCV RNA
remained undetectable during the entire 48 week treat-
ment course and these patients reached SVR. In
contrast, the viraemia reappeared under treatment at
24 weeks in patient 2 (genotype 3a) without elevation of
liver enzymes. This situation was considered as a failure
of therapy and Pegasys treatment was stopped.
Most of the observed side effects such as anorexia,
weight loss, insomnia, depression and ﬂu-like symp-
toms were predictable and manageable. Myelotoxicity
was mitigated by strict adherence to the dose-
reduction schedule, so that neutropoenia and throm-
bopoenia remained moderate and not associated with
clinically related events. Anaemia needed an increase
of recombinant epoetin doses, enabling haemoglobin
levels to be maintained without blood transfusions.
Two adverse events were peculiar and deserve a special
description. Patient 2 complained of chronic dry cough
associated with bilateral interstitial inﬁltrates on chest
X-ray. Both cough and lung inﬁltrates disappeared
when dry weight was decreased and recurred 4 months
after Pegasys therapy was stopped. Extensive inves-
tigations revealed mixed interstitial and obstructive
bronchopneumopathy. Oral steroids allowed resolu-
tion of symptoms, but minimal lung inﬁltrates per-
sisted. A side effect of Pegasys treatment could not
be ruled out. Patient 3 presented cutaneous bullous
lesions on both hands, diagnosed as pseudoporphyria
cutanea, after 8 months of Pegasys treatment.
Furosemide, a frequent cause of dialysis-related
pseudoporphyria cutanea, was stopped and the lesions
progressively disappeared within 3–4 months. Thus,
whether this side effect was attributable to Pegasys or
not remains unclear.
Discussion
Conventional interferon in monotherapy leads to SVR
rates of 30–40% in patients on dialysis [1]. However,
a high percentage of adverse events and early dis-
continuations makes this treatment difﬁcult to apply in
these patients. PEG–interferon-a-2a and 2b have
signiﬁcantly improved antiviral therapy for HCV in
patients without renal insufﬁciency [3,4]. Furthermore,
PEG–interferon-a-2a is more efﬁcient than standard
interferon-a-2a in HCV patients with genotype 1 [3].
This report is the ﬁrst to describe the use of pegylated
interferon in haemodialysed patients. PEG-interferon-
a-2a was chosen since this compound is mostly cleared
via hepatic metabolism, in contrast to PEG-inter-
feron-a-2b, which essentially shows renal clearance.
Table 1. Treatment schedule and monitoring of side effects
Parameter Downward dose adjustment of PEG–interferon
Neutrophil count (cell/mm3)
>1000 None
750–999 Weeks 1–2: immediate one level adjustment
Weeks 3–48: no adjustment
500–749 Weeks 1–2: delay or hold dose until >750,
then resume dose with one level adjustment
Weeks 3–48: Immediate one level adjustment
250–499 Weeks 1–2: Delay or hold dose until >750,
then resume dose with two level adjustment
Week 3–48: Delay or hold dose until >750,
then resume dose with one level adjustment
<250 Stop drug
Platelet count (cell/mm3)
>50 000 None
35 000–49 000 Delay or hold dose until >50 000,
then resume dose with one level adjustment
25 000–34 000 Delay or hold dose until >50 000,
then resume dose with two level adjustment
<25 000 Stop drug
Pegasys (40 kDa branched PEG–interferon-a-2a) dose adjustments
for low absolute neutrophil and platelet counts: assigned dose,
Pegasys 180mg; one level adjustment, Pegasys 135mg; two level
adjustment, Pegasys 90mg; three level adjustment, Pegasys 45 mg.
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Furthermore, its pharmacokinetics following a single
dose subcutaneous administration are already known
in patients with ESRD [5]. In the latter study, different
pharmacokinetic parameters were assessed using
ascending doses of Pegasys. The dose of 180 mg led
to the highest area under the curve, but serum half-life
and maximal concentrations of the drug were similar to
those seen in healthy subjects [5]. Thus, we elected to
initiate the treatment at this dose, being prepared to
reduce it according to weekly clinical and haematolo-
gical observations.
In patients without renal insufﬁciency, acute
hepatitis C can be treated successfully in 24 weeks [6].
However, the natural history of HCV acute infection
in dialysed patients is less predictable and usually less
favourable [7,8]. In the absence of guidelines in this
particular setting, we felt that a treatment of 48 weeks
in patient 3 might have given the best chance to
eradicate the virus in order to make the patient eligible
to receive a renal transplant.
SVR was observed in both HCV patients with
genotype 1b, which is a remarkable ﬁnding since this
genotype is typically associated with lower success
rates. There was no serious adverse event and the
reported side effects were manageable by appropriate
dose reductions.
Conclusion
In this cumulative experience of 30 months, PEG–
interferon-a-2a appears to be an interesting treatment
option in HCV patients undergoing maintenance
haemodialysis. Large controlled studies are now
needed to conﬁrm these encouraging preliminary data.
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Table 2. Treatment, responses and side-effects
Patient 1 Patient 2 Patient 3
Liver disease Chronic hepatitis Cirrhosis Child A Acute hepatitis
HCV genotype 1b 3a 1b
Effective treatment duration 48 weeks 24 weeks 48 weeks
Weekly dose and causes of
dose adjustments
180mg for 48 weeks 180mg for 4 weeks
Decrease to 90 mg for 2 weeks
(thrombopoenia, insomnia)
180mg for 7 weeks
Decrease to 135mg for 4 weeks
(neutropoenia)
Increase to 135mg for 10 weeks Decrease to 90mg for 37 weeks
(neutropoenia and depression)
Decrease to 90 mg for 8 weeks
(thrombopoenia)
HCV RNA level at 72 weeks (SVR) Not detectable 189 kIU/ml at 24 weeks Not detectable
ALAT Normalized at 12 weeks Normal (entire follow-up) Normalized at 4 weeks
Minimal Hb level (g/l) 103 92 125
Minimal leukocyte count (G/L) 2.8 2.8 1.3
Minimal neutrophil count (G/L) 1.0 1.4 0.5
Minimal platelet count (G/L) 107 49 107
Side effects None Weight loss, insomnia (oxazepam
prescription), cough and X-ray
inﬁltrates
Weight loss, fatigue, depression
(citalopram prescription)
ﬂu-like symptoms,
cutaneous bullous lesions
G/L=giga/liter
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